Last reviewed · How we verify
Encordin (peruvoside)
Encordin (generic name: peruvoside) is a peruvoside drug. It is currently in unknown development.
Encordin works by binding to a specific target, but the exact nature of this interaction is unknown.
Encordin is a small molecule with synonyms including Peruvoside, and it is used to treat heart failure.
At a glance
| Generic name | peruvoside |
|---|---|
| Drug class | peruvoside |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine Encordin as a key that fits into a lock on a cell. When it binds to its target, it can either block or enhance the cell's activity, depending on the specific mechanism. However, without more information, it's difficult to say exactly how Encordin interacts with its target.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Encordin CI brief — competitive landscape report
- Encordin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Encordin
What is Encordin?
How does Encordin work?
What is the generic name of Encordin?
What drug class is Encordin in?
What development phase is Encordin in?
Related
- Drug class: All peruvoside drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing